Company profile for Clover Biopharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Founded by a team of world-class scientists returning to China, Clover Biopharmaceuticals is passionate about developing transformative biologic therapies for the millions of Chinese patients who currently do not have access to modern biological medicines. Seeking to Change the Paradigm in China | Emerging only recently from the advent of modern biotechnology, biologics today represent the majority of the world’s most effica...
Founded by a team of world-class scientists returning to China, Clover Biopharmaceuticals is passionate about developing transformative biologic therapies for the millions of Chinese patients who currently do not have access to modern biological medicines. Seeking to Change the Paradigm in China | Emerging only recently from the advent of modern biotechnology, biologics today represent the majority of the world’s most efficacious therapies due to their high target specificity and lower off-target toxicities compared to small molecule drugs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
B-A10 Room No.1, Mansion Chengdu Hi-tech Zone Hi-tech Incubation Park, Tianhe ...
Telephone
Telephone
(028)85336966
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/clover-appoints-nicholas-jackson-phd-as-president-of-global-rd-and-alliances-302588366.html

PR NEWSWIRE
20 Oct 2025

https://www.prnewswire.com/news-releases/clover-announces-us-ind-clearance-and-initiation-of-revaccination-clinical-study-for-rsv-vaccine-candidate-scb-1019-302408671.html

PR NEWSWIRE
23 Mar 2025

https://www.prnewswire.com/news-releases/clover-announces-positive-clinical-data-for-rsv-vaccine-candidate-scb-1019-compared-head-to-head-versus-gsks-arexvy-302289224.html

PR NEWSWIRE
28 Oct 2024

https://www.prnewswire.com/news-releases/clover-announces-positive-preliminary-phase-i-results-for-bivalent-rsv-vaccine-candidate-scb-1019-in-initial-young-adult-cohort-302110248.html

PR NEWSWIRE
08 Apr 2024

https://www.prnewswire.com/news-releases/clover-initiates-phase--clinical-trial-for-rsv-vaccine-candidate-302013309.html

PR NEWSWIRE
12 Dec 2023

https://www.globenewswire.com//news-release/2023/09/12/2741223/0/en/Clover-Launches-Quadrivalent-Seasonal-Influenza-Vaccine-in-Mainland-China.html

GLOBENEWSWIRE
11 Sep 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty